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ABSTRACT 
Background Context: Cervical Spondylotic Myelopathy (CSM) is a progressive, degenerative 
condition and the most common cause of spinal cord dysfunction worldwide. A timed 30-meter 
walking test (30MWT) has previously been recommended for testing disease severity in patients 
with CSM because of its objectivity, quantitative nature, and ease of administration. However, 
very little has been reported in the literature regarding its use.  
Study Design/Setting:  We utilized data from two prospective CSM cohort studies to analyze properties 
of the 30MWT test for patients with CSM. All patients had symptomatic CSM and subsequently 
underwent surgical decompression. Each patient completed 3 trials of the 30MWT at baseline as well as 
6, 12, and 24 months following surgery. 
Methods: Repeated measures analysis of variance (ANOVA) was used to examine test reproducibility, 
and Spearman’s correlation coefficients were used to compare the results of the 30MWT to other 
validated scales used in the CSM population. Additionally, we used paired T-tests to assess the difference 
between baseline and 6-month post-operative 30MWT times. Standardized response mean was used to 
measure responsiveness.  
Results: Moderate correlation (-0.551) was seen between the 30MWT and the modified Japanese 
Orthopedic Association (mJOA) scale as well as the Nurick score (0.468) at baseline.  Low correlation 
was found between the 30MWT and the NDI (0.253) as well as the physical component of the Short-
Form 36 Health Survey (-0.380). Walking time did not vary significantly between the three trials at 
baseline (p = 0.66). At 6 months post-op, patients completed the 30MWT 9.9 seconds faster compared to 
baseline (p < 0.0001).    
Conclusions: The results from two prospective cohort studies demonstrate that the 30MWT is 
reproducible and moderately correlated with other validated scales used with CSM patients. Because the 
30MWT is simple, quick, affordable, and assess gait parameters not accurately assessed by other standard 
metrics, it should be used as an ancillary test for CSM patients. 
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INTRODUCTION  
Cervical Spondylotic Myelopathy (CSM) is a progressive, degenerative condition which causes 
chronic compression of the cervical spinal cord.
1
  As the most common cause of spinal 
dysfunction worldwide, the incidence of CSM-related hospitalizations has been estimated to be 
4.04/100,000 person-years.
2
 However, estimations of the incidence of this disease have been 
difficult to ascertain due to ambiguous classification of CSM by diagnosis codes and a paucity of 
relevant literature.
3
 CSM may cause symptoms such as tingling,  numbness and weakness of the 
upper and lower extremities, spasticity, difficulty walking, neck pain, and impotence.
4
 If left 
untreated, CSM may lead to quadriplegia. After the diagnosis of CSM has been made, surgery 
has been shown to be an effective modality for relieving the symptoms of CSM and halting the 
progression of disease.
5-7
 Several measures have been used to quantify the severity of disease 
among patients with CSM, with the Nurick Scale and Modified Japanese Orthopedic Association 
Scale (mJOA) being the most commonly used in the literature.
8, 9
 Other common measures 
include the Visual Analog Scale (VAS) for pain, the Short-Form 36 (SF-36v2), the Neck 
Disability Index (NDI), and the Myelopathy Disability Index (MDI).
10
 Despite the frequent use 
of these measures, these assessments do not specifically address the gait dysfunction seen in 
CSM in an objective, quantifiable manner.
8, 9, 11, 12
  
The 30-meter Walking Test (30MWT) was described in 1999 as a quantitative and 
objective test used for patients with Cervical Spondylotic Myelopathy.
12
 The 30MWT is 
conducted by simply measuring the time taken by a patient to walk 30 meters. Taking a longer 
amount of time to walk 30 meters reflects greater disability. The 30MWT has been 
recommended for use in any clinical practice with patients with CSM, as well as for researchers 
studying CSM.
8
 In addition, the test has been used in the chronic obstructive pulmonary disease 
(COPD) population.
13
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Although the 30MWT is recommended for use in patients with CSM, very little has been 
reported in the literature regarding its use. In the original validation study, only 41 patients with 
CSM were evaluated. Additionally, the walking test results were only compared to the MDI and 
Nurick Scales. In order to provide more information on 30MWT reproducibility, validity, and 
responsiveness, we conducted a retrospective cohort analysis using data from two recent CSM 
prospective multicenter cohort studies. 
METHODS 
Subjects 
We conducted a cohort analysis using data from two CSM studies: the AOSpine North America 
prospective multi-center study and the AOSpine International prospective multi-center study.
6, 14
 The 
AOSpine North America study was conducted between December 2005 and September 2007, enrolling a 
total of 278 patients. The AOSpine International study was conducted between October 2007 and January 
2011, enrolling 479 patients. The key inclusion criteria were age of eighteen years or older, symptomatic 
CSM (secondary to either disc herniation, ossification of the posterior longitudinal ligament, ligamentum 
flavum hypertrophy, spondylosis, subluxation, or a combination of these changes), objective cervical cord 
compression as determined by magnetic resonance imaging (MRI), no prior surgical treatment for 
myelopathy, and the absence of symptomatic lumbar stenosis. A total of 757 patients were enrolled 
between the two studies. All participating patients provided informed consent.  Investigators received 
approval to conduct the study from their Institutional Review Board.  
Measures 
 For the 30MWT, each patient is asked to walk the 30-meter distance as quickly as he or she feels 
comfortable. Patients are allowed to use assistive devices that they would normally use (e.g. cane, 
walker).  The 30MWT was repeated three times at each visit, and each iteration was timed by trained 
study coordinators. Several other validated measures were used to assess the severity of CSM. These 
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include the mJOA, Nurick scale, Neck Disability Index (NDI), and the Short-Form-36 (SF-36v2). 
Information was obtained at baseline and post-operatively at 6, 12, and 24 months.   
Statistical Analysis 
To determine the reliability and reproducibility of the 30MWT, repeated measures analysis of variance 
(ANOVA ) was used to determine possible differences between each trial given at baseline. In order to 
examine the validity of the walking test, we used correlation coefficients to compare the results of the 
30MWT walking test to other validated scales including the Nurick, mJOA, NDI, and physical and mental 
component summary scores of the SF-36v2. We report the correlations compared to several other 
validated scales since currently no gold standard test exists in this field. Additionally, we assess the 
difference between baseline walking test times and walking test times six months post-operation. In order 
to incorporate patients who were unable to complete the walking test due to physical inability (e.g. 
wheelchair-bound) into some of the analyses (correlation and paired differences), we assigned those 
patients a time which corresponded with the highest recorded walking test time of any patient at baseline. 
By doing this, patients who may have lost or gained the ability to walk following surgery could be 
conservatively included in the statistical analysis. We conducted a sensitivity analysis to see the impact of 
this assumption by running an additional analysis with these patients excluded. Nonparametric Spearman 
correlation coefficients and the Wilcoxon signed rank test were used when patients who were unable to 
walk were included in the analysis, and parametric Pearson correlation coefficients and the paired t-test 
were used in the sensitivity analysis. To determine the responsiveness of the 30MWT, the effect size and 
standardized response mean were used to assess responsiveness at 6 months follow-up. Significance for 
all statistical tests used was set at an alpha level of .05. Statistical analysis was conducted using SAS 
version 9.4 for Windows (Cary, NC). 
RESULTS 
Table 1 shows the demographics of the study population. Of the 757 total patients enrolled 
between the two trials, data from at least one baseline walking test were available for 612 
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patients. The average time for the 30MWT was 33.8 seconds among these patients (standard 
deviation, 18.2 seconds; Median, 28.5; 25% Q1: 23 seconds; 75% Q3 37 seconds). These times 
ranged from a low of 13.33 seconds to a high of 146 seconds at baseline.  
Table 1: Combined Cohort Demographics 
General Characteristic Means or Frequencies 
Age (years) 56.4±11.8 
Gender (male) 475 (62.75%) 
Duration of Symptoms 
(months) 
26.6±39.0  
Weight (pounds) 171.2 
Height (inches) 66.3 
Body Mass Index 27.3 
Race 
   White or Caucasian 
   Black or African-American 
   East Asian 
   Other  
 
73.1% 
6.21% 
15.2% 
5.49% 
Region    
   North America 
   Asia Pacific 
   Europe 
   Latin America 
   
 
52.97% 
19.82% 
16.64% 
10.57% 
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Reproducibility 
Between the two cohorts, 479 patients completed the walking test all three times at their baseline 
visit. ANOVA failed to show a statistically significant difference between these 30MWT trials (p 
= 0.663). Because no significant difference was seen between trials, each patient’s average time 
over all three walking trials was used for further data analysis. 
Correlation 
Table 2 shows the Spearman correlation coefficients between the 30MWT and other validated 
scales at baseline and 6 months post-operation. These scales included the Nurick scale, mJOA, 
NDI, and physical and mental component summary scores of the SF-36v2. At baseline, the 30MWT 
demonstrated moderate correlation with the Nurick (-0.468) and the mJOA (-0.551). Moderately low 
correlation was seen between the 30MWT and the SF-36v2 physical component summary score (-0.380) 
while very low correlation was seen between the 30MWT and the Neck Disability Index (0.253) and 
mental component summary score of the SF36v2 (-0.274). The correlations between the 30MWT and 
other tests were comparable at 6 months following surgery. All 10 of the reported correlation coefficients 
were statistically significant (p < 0.0001). 
Table 2: Correlations between 30MWT and Other Selected Measures at Baseline and 6 Months 
Comparator 
with 30MWT 
Number of 
patients for 
comparison at 
Baseline 
Walking Test 
Correlation at 
Baseline 
Number of 
Patients for 
Comparison 
at 6 Months 
Walking Test 
Correlation at 6 
Months, N 
Nurick 680 0.468 573 -0.369 
mJOA 680 -0.551 573 -0.520 
NDI 593 0.253 513 0.304 
SF-36v2 PCS 663 -0.380 563 -0.351 
SF-36v2 MCS 663 -0.274 563 -0.286 
All correlations were statistically significant at p < 0.0001. Nurick indicates Nurick scale; mJOA, modified 
Japanese Orthopedic Association; NDI, Neck Disability Index; SF-36v2, Short-form 36; PCS, physical 
component score; MCS, mental component score 
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Differences in 30MWT Time Following Surgery 
Data for the 30MWT data were available at both baseline and 6 months following surgery for a 
total of 545 patients. The mean reduction in walking time at 6 months was found to be 9.93 
seconds. This change was statistically significant (p < 0.0001) using the nonparametric Wilcoxon 
signed rank test.  
Responsiveness 
Effect size and standardized response mean were both calculated to examine the responsiveness 
of the 30MWT. Effect size is calculated by dividing the mean change between baseline and 
follow-up by the standard deviation of the baseline score. Similarly, standardized response mean 
is calculated by dividing the mean change between baseline and follow-up by the standard 
deviation of the individual changes in scores. Both effect size and standardized response mean 
can range from 0 to 1, with 1 representing perfect test responsiveness. Table 3 shows the results 
were 0.264 for the effect size and 0.327 for the standardized response mean. Because the 
30MWT is expected to be more responsive for patients with CSM who have difficulty walking, 
effect size and standardized response mean were also calculated using samples of the overall 
study population. As expected, the responsiveness of the 30MWT increased when limiting the 
analysis to the top 50% and 25% of patients according to walking time (Table 3).  
Table 3: 30MWT Responsiveness by Subpopulation 
Sample N SRM ES 
All 545 0.327 0.264 
Top 50% of cohort 
according to walking 
293 0.461 0.420 
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time (30MWT > 28.5 
seconds) 
Top 25% of cohort 
according to walking 
time (30MWT > 37 
seconds) 
169 0.600 0.638 
 
Sensitivity Analysis 
In the sensitivity analysis for correlation, 70 patients who were unable to walk at either the 
baseline or 6-month visit were removed from the analysis. Parametric tests were used for the 
sensitivity analysis because removing the 70 patients with a high walking time caused the data to 
be normally distributed. Regarding the relationship between the 30MWT and the other scales, 
the results demonstrated slightly different Pearson correlation coefficients compared to the 
corresponding Spearman correlation coefficients. The 30MWT showed low-moderate correlation 
with the Nurick (0.360) and mJOA (-0.403) and continued to show low correlation between the 
30MWT and the NDI (0.187), physical component of the SF-36v2 (-0.288) and mental 
component of the SF-36v2 (-0.200). All p values remained less than 0.0001. When patients who 
were unable to walk were removed at baseline and six months, the mean reduction in walking 
time was 3.96 seconds among 488 patients compared to 9.93 seconds among 545 patients. This 
reduction in walking time was still statistically significant using paired a paired t-test (p < 
0.0001). Table 3 shows the effect size and standardized response mean adjusted for the 
sensitivity analysis. Because the standard deviation was lower when removing these patients, the 
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responsiveness actually showed an increase in those with difficulty walking (top 50% and 25% 
of cohort according to walking time).  
Table 4: 30MWT Responsiveness by Subpopulation in Sensitivity Analysis 
Sample N SRM ES 
All 488 0.316 0.247 
Top 50% of cohort 
according to walking 
time (30MWT > 28.5) 
236 0.474 0.455 
Top 25% of cohort 
according to walking 
time (30MWT > 37) 
112 0.611 0.695 
 
DISCUSSION AND CONCLUSION  
Singh and Crockard developed the 30MWT and reported preliminary data on 41 patients 
with CSM in 1999.
12
 Our study reexamines the test characteristics of the 30MWT using data 
from two recent prospective multicenter cohort studies. According to our results, the test was 
reproducible, as no significant difference was seen between each trial of the 30MWT given at 
baseline. Moreover, the 30MWT demonstrated moderate correlation with both the Nurick scale 
(0.468) and mJOA (-0.551), which are the most widely used measures in the CSM population
8
. 
Compared to the original 1999 validation study, our results demonstrated lower correlation 
between the 30MWT and the Nurick scale, as they reported a correlation of 0.61 and 0.69 at 
baseline and 2 months following surgery, respectively. A recent study examining the validity of 
the mJOA using patients from the CSM North America study, who were included in the current 
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study, reported a correlation between the mJOA and 30MWT of -0.382. This value is similar to 
the association that we report in our sensitivity analysis when patients who were unable to walk 
were excluded from the analysis. Finally, our results indicate that the responsiveness of the 
30MWT, although low when calculated for all patients with CSM, increases to moderate when 
only patients with difficulty walking are included in the analysis. This makes sense, as we expect 
the 30MWT to only be helpful for assessing CSM severity in patients who have difficulty 
walking. Our sensitivity analysis showed that our assumption of imputing walking test times for 
patients unable to complete the walking test due to physical inability was valid. A significant 
change in walking time was still seen in the study population when patients unable to walk were 
excluded, and the test responsiveness was actually higher when removing those patients.  
Several scales and scoring systems have been used to quantify the severity of CSM. 
These measures are vulnerable to several limitations, however. First of all, most of these 
measures rely on information reported by patients themselves, lacking the objectivity of a 
neurologic examination. Second, many measures are long questionnaires which may require a 
trained study coordinator or other aide to spend significant time with the patient in clinic. Third, 
currently used measures may not be available in resource-poor areas and often times have not 
been validated in other languages besides English. In contrast, the 30MWT objectively assesses 
gait parameters that are not accurately assessed by other metrics.  
Our study has several limitations. First, reproducibility was assessed by timing the 
30MWT for three trials on the same day at each visit. While this method provides a degree of 
information regarding reproducibility, it does not assess reproducibility from day to day and may 
fail to capture fluctuations in functional status. Additionally, only 545 of 757 patients had 
walking test data at both baseline and six months. This may introduce a selection bias via 
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selective follow-up. However, this study also has several strengths. First, our research utilized a 
multicenter international prospective study design with few inclusion criteria and many 
investigators. All of these characteristics increase the study’s external validity and contribute to 
its real-world applicability. Furthermore, the severity of CSM was measured using several 
validated instruments, which allowed for proper comparison and correlation with the 30MWT.  
Practically speaking, the 30MWT should not be considered a replacement for the mJOA 
or the Nurick scale, but it will act as a complementary test by providing an objective measure of 
gait not easily captured by other commonly used metrics.  It is simple, objective, reproducible, 
and easy for patients and clinicians to perform.  Language is not a barrier to its performance, and 
the continuous, objective measurement is useful in research settings.  Additionally, it does not 
require sophisticated equipment to perform. Along with these unique advantages, the testing 
characteristics associated with the 30MWT, computed using data from two prospective multi-
center cohort studies, suggest that the 30MWT is a useful ancillary test for measuring the 
severity of CSM. 
 
 
 
 
 
 
 
 
 
11 
 
 
REFERENCES 
1. Karadimas SK, Erwin WM, Ely CG, Dettori JR, Fehlings MG. Pathophysiology and 
natural history of cervical spondylotic myelopathy. Spine. 2013;38:S21-36. 
2. Wu JC, Ko CC, Yen YS, et al. Epidemiology of cervical spondylotic myelopathy and its 
risk of causing spinal cord injury: a national cohort study. Neurosurgical focus. 
2013;35:E10. 
3. Nouri A, Tetreault L, Singh A, Karadimas SK, Fehlings MG. Degenerative Cervical 
Myelopathy: Epidemiology, Genetics and Pathogenesis. Spine. 2015. 
4. Tetreault LA. A clinical prediction model to determine outcomes in patients with cervical 
spondylotic myelopathy undergoing surgical treatment: data from the prospective, multi-
center AOSpine North America study. Journal of bone and joint surgery American 
volume. 2013;95:1659-66. 
5. Furlan JC, Kalsi-Ryan S, Kailaya-Vasan A, Massicotte EM, Fehlings MG. Functional 
and clinical outcomes following surgical treatment in patients with cervical spondylotic 
myelopathy: a prospective study of 81 cases. J Neurosurg Spine. 2011;14:348-55. 
6. Fehlings MG. Efficacy and safety of surgical decompression in patients with cervical 
spondylotic myelopathy: results of the AOSpine North America prospective multi-center 
study. Journal of bone and joint surgery American volume. 2013;95:1651-8. 
7. Rhee JM, Shamji MF, Erwin WM, et al. Nonoperative management of cervical 
myelopathy: a systematic review. Spine. 2013;38:S55-67. 
8. Kalsi-Ryan S, Singh A, Massicotte EM, et al. Ancillary outcome measures for assessment 
of individuals with cervical spondylotic myelopathy. Spine. 2013;38:S111-22. 
12 
 
9. Kopjar B, Tetreault L, Kalsi-Ryan S, Fehlings M. Psychometric properties of the 
modified Japanese orthopaedic association scale in patients with cervical spondylotic 
myelopathy. Spine. 2015;40:E23-8. 
10. Zhang Y, Zhou F, Sun Y. Assessment of health-related quality of life using the SF-36 in 
Chinese cervical spondylotic myelopathy patients after surgery and its consistency with 
neurological function assessment: a cohort study. Health and quality of life outcomes. 
2015;13:39. 
11. Singh A, Tetreault L, Casey A, Laing R, Statham P, Fehlings MG. A summary of 
assessment tools for patients suffering from cervical spondylotic myelopathy: a 
systematic review on validity, reliability and responsiveness. European spine journal : 
official publication of the European Spine Society, the European Spinal Deformity 
Society, and the European Section of the Cervical Spine Research Society. 2013. 
12. Singh A, Crockard HA. Quantitative assessment of cervical spondylotic my elopathy by a 
simple walking test. The Lancet. 1999;354:370-3. 
13. Andersson M, Moberg L, Svantesson U, Sundbom A, Johansson H, Emtner M. 
Measuring walking speed in COPD: test-retest reliability of the 30-metre walk test and 
comparison with the 6-minute walk test. Primary care respiratory journal : journal of the 
General Practice Airways Group. 2011;20:434-40. 
14. Tetreault L, Cote P, Kopjar B, et al. A Clinical Prediction Model to Assess Surgical 
Outcome in Patients with Cervical Spondylotic Myelopathy: Internal and External 
Validation using the Prospective Multicenter AOSpine North American and International 
Datasets of 743 Patients. The spine journal : official journal of the North American Spine 
Society. 2014. 
